Everything below concerns Angiotensin IV analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
=== On Mars === Thiophene derivatives have been detected at nanomole levels in 3.5 billions year old Martian soil sediments (Murray Formation, Pahrump Hills) by the rover Curiosity at Gale crater (Mars) between 2012 and 2017.
=== Background === Influenced by strategic analyses such as the 1976 Team B report—which argued U.S. intelligence had vastly underestimated Soviet threats—and ideas of the Citizens' Advisory Council on National Space Policy, President Ronald Reagan announced the Strategic Defense Initiative (SDI) in 1983. It proposed a space-based global missile defense constellation intended to render nuclear weapons "impotent and obsolete." The program immediately faced challenges, with concerns by Congress, including prominent senators Sam Nunn and Joe Biden, over its apparent violation of the Anti-Ballistic Missile Treaty, questionable technical feasibility, spiraling launch costs, poor cost-exchange ratio, and destabilizing impact on arms control. By the 1990s, SDI was formally restructured into the Ballistic Missile Defense Organization, pivoting from space-based platforms to more proven ground- and sea-based systems. U.S. missile defense policy continued to evolve, with the 1999 National Missile Defense Act mandating a system to defend against limited ballistic missile attacks. Following a later Team B report's recommendation, President George W. Bush withdrew the U.S. from the ABM Treaty in 2001. The Obama administration's 2010 Review shifted focus from a homeland-centered shield to more flexible and cooperative regional defenses, limiting the space component to sensing and tracking. This was adjusted by the Trump administration's 2019 Review, expanding scope from rogue states such as North Korea, to include advanced hypersonic threats from "competitors" like Russia and China.
In the cytosol, acetyl-CoA carboxylase (ACC) generates malonyl-CoA from acetyl-CoA and CO2 and is responsible for the majority of the cellular malonyl-CoA pool. The amount of malonyl-CoA in the cytosol is tightly regulated by the opposing activities of ACC and malonyl-CoA decarboxylase (MCD), which catalyzes the reverse reaction to produce acetyl-CoA and CO2. Cytosolic malonyl-CoA plays a key role in regulating fatty acid metabolism. Although malonyl-CoA itself cannot enter mitochondria, malonate produced through non-enzymatic hydrolysis of cytosolic malonyl-CoA may cross membranes and contribute to the mitochondrial malonyl-CoA pool. In mitochondria, the malonyl-CoA pool is generated by acyl-CoA synthetase family member 3 (ACSF3), which catalyzes the thioesterification of malonate and CoA, and by a mitochondrial isoform of acetyl-CoA carboxylase 1 (mtACC1), which produces malonyl-CoA through the carboxylation of acetyl-CoA and CO2. Complementing these synthetic activities, MCD likeweise operates in mitochondria, where it converts malonyl-CoA back to acetyl-CoA and CO2. Mitochondrial malonyl‑CoA is essential for local protein malonylation as well as for mitochondrial fatty acid synthesis (mtFAS). In the nucleus, malonyl-CoA is synthesized by ACC1, which is mainly cytoplasmic, suggesting a local and possibly unconventional function. The extent of malonylation increases with malonyl‑CoA availability particularly under conditions such as metabolic stress or enzyme deficiencies, for example malonyl‑CoA decarboxylase deficiency.
=== North Atlantic === Recipes for fish maw, specifically codfish maw, are documented in Hannah Glasse's 1747 English cuisine cookbook The Art of Cookery Made Plain and Easy: fish maw is presented in gravy, broiled, and as a fricassee. Cod maw was later described as a 'delicacy' in the 1911 American food industry encyclopedia, The Grocer's Encyclopedia, by Artemas Ward. Cod maw is a traditional food of Newfoundland, owing to the ubiquity of the cod fishing industry. It was typically salted for preservation until use, then boiled and stewed. The popularity of cod maw dropped in the late 20th century along with cod tongue and cheeks, but has begun to see a resurgence with culinary tourism and interest in nose to tail eating. In Portugal, Codfish maw (Portuguese: sames) was salted and brought to shore to be eaten as a fisherman's dish. Portuguese sailors from Figueira da Foz would rely on codfish maw as a byproduct of cod fishing in Newfoundland. Feijoada is traditionally made with fish maw instead of pork in Figueira da Foz (Feijoada de sames).
=== Primary dentin === Primary dentin, the most prominent dentin in the tooth, lies between the enamel and the pulp chamber (near dentinoenamel junction). The outer layer closest to enamel is known as mantle dentin. This layer is unique to the rest of primary dentin. Mantle dentin is formed by newly differentiated odontoblasts and forms a layer consistently 15-20 micrometers (μm) wide. Unlike primary dentin, mantle dentin lacks phosphorylation, has loosely packed collagen fibrils and is less mineralized. Below it lies the circumpulpal dentin, more mineralized dentin which makes up most of the dentin layer and is secreted after the mantle dentin by the odontoblasts. Circumpulpal dentin is formed before the root formation is completed. Newly secreted dentin is unmineralized and is called predentin. It is easily identified in hematoxylin and eosin stained sections since it stains less intensely than dentin. It is usually 10-47μm and lines the innermost region of the dentin. It is unmineralized and consists of collagen, glycoproteins, and proteoglycans. It is similar to osteoid in bone and is thickest when dentinogenesis is occurring.
Sources: en.wikipedia.org
On the other hand, the reticular fiber of the capillary sheath resembled the basement membrane of the capillary in its components. Because of their affinity for silver salts, these fibers are called argyrophilic.
The first application of 238Pu was its use in nuclear weapon components made at Mound Laboratories for Lawrence Radiation Laboratory (now Lawrence Livermore National Laboratory). Mound was chosen for this work because of its experience in producing the polonium-210-fueled Urchin initiator and its work with several heavy elements in a Reactor Fuels program. Two Mound scientists spent 1959 at Lawrence in joint development while the Special Metallurgical Building was constructed at Mound to house the project. Meanwhile, the first sample of 238Pu came to Mound in 1959. The Milliwatt Radioisotopic Thermoelectric Generator is used to provide power to Permissive Action Links (PAL) in US nuclear weapons.
=== Taxidermy === Freeze-drying is among the methods used to preserve animals in the field of taxidermy. When animals are preserved in this manner they are called "freeze-dried taxidermy" or "freeze-dried mounts". Freeze-drying is commonly used to preserve crustaceans, fish, amphibians, reptiles, insects, and smaller mammals. Freeze-drying is also used as a means to memorialize pets after death. Rather than opting for a traditional skin mount when choosing to preserve their pet via taxidermy, many owners opt for freeze-drying because it is less invasive upon the pet's body.
Liu had seized the Chengdu Arsenal in 1925 after Yang Sen's downfall, but to appease the city's other warlords, he announced plans to convert it into a mechanical repair shop rather than a weapons factory. To oversee this process, he appointed his brother Liu Wencheng, who had previously run a distillery, as its manager. Liu Wencheng would also later be appointed to several managerial positions in industrial enterprises. The Chengdu Arsenal would eventually be converted into a mint, increasing Liu Wenhui's money supply. Liu's brother Wencheng used his position in Chengdu to purchase houses and land, expanding his family's real estate holdings. He purchased so much property that his rivals nicknamed him "Liu Half-City", implying he owned half of Chengdu. Liu Wenhui's army continued growing due to money and industrial supplies from his brothers. Over the course of 1926, he attacked and disarmed the forces of Yang Chunfang in January and Lü Chao in April, taking control of Lü's territories in southern Sichuan. To formalize the division of Chengdu, Liu, Deng, and Tian established a joint command in December 1926 with Liu as director. In December 1926, communist forces under Liu Bocheng launched the Luzhou Uprising in Sichuan as part of the Northern Expedition. Liu Bocheng's forces successfully took control of the city from warlord Lai Xinhui. Control of Luzhou was coveted by several neighboring warlords, who had also begun besieging the city. To prevent his rivals from capturing Luzhou, Liu dispatched his friend Leng Yingdong to surround the city in April 1927.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.